BUZZ-停止肺病药物后期试验后,MannKind业绩下滑

路透中文
Nov 10, 2025
BUZZ-停止肺病药物后期试验后,MannKind业绩下滑

11月10日 - ** 制药商MannKindMNKD.O的股价下跌7.5%,至5.2美元,该公司停止了 (link)。

** 盘初股价创下逾三周新低

** 该公司称,其MNKD-101药物是一种有望治疗非结核分枝杆菌(NTM) 肺病的雾化版本,但在最初的46名患者中没有显示出治疗成功的迹象。

** 数据安全监测委员会对中期数据进行了审查,并同意 co 因无效而终止试验;研究期间未发现任何安全问题

** MNKD将重点放在MNKD-102上,这是一种干粉吸入制剂,仍处于早期开发阶段,因为其雾化版本未能显示出疗效。

** MNKD 年内下跌 18

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10